Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 4/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20466171 | 0.84 | MAOA (0.53) | IAPPMAOAMAOBCYP19A1THRA | |
| SCHEMBL22423216 | 0.83 | IAPP (0.56) | IAPPFFAR1TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL1818277 | 0.82 | ALDH1A1 (0.60) | IAPPMAOAMAOBCYP19A1THRA | |
| SCHEMBL10694899 | 0.81 | IAPP (0.57) | IAPPTHRATHRBFFAR1TDP1 | |
| SCHEMBL28910429 | 0.81 | IAPP (0.62) | IAPP | |
| SCHEMBL360723 | 0.80 | THRA (0.62) | MAOAMAOBCYP19A1THRATHRB | |
| SCHEMBL4604250 | 0.80 | MAOA (0.57) | MAOAMAOBCYP19A1THRATHRB | |
| SCHEMBL28186660 | 0.80 | MAOA (0.57) | MAOAMAOBCYP19A1THRATHRB | |
| SCHEMBL23901663 | 0.79 | IAPP (0.56) | IAPPMAOBFFAR1 | |
| SCHEMBL1068218 | 0.79 | CYP4F2 (0.55) | MAOAMAOBCYP19A1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-9555035-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20160331753-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| US-9428499-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2016-08-30 | — | — | US | disclosed |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331753-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | IAPP 4550/4885MAOA 1014/4885MAOB 711/4885 |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | IAPP 4550/4885MAOA 1014/4885MAOB 711/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | IAPP 195/4885MAOA 1516/4885MAOB 1282/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | IAPP 195/4885MAOA 1516/4885MAOB 1282/4885 |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | IAPP 4550/4885MAOA 1014/4885MAOB 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.